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Both environmental and endogenous oestrogens have been consid-
ered a cause of breast and reproductive-tract cancers (La-Vecchia
et al, 1993; McPherson et al, 1996; Leon and Ben-Shlomo, 1997;
Møller and Skakkebæk, 1997; Swerdlow et al, 1997a; Thomas et
al, 1997). It has been further suggested that high levels of endoge-
nous oestrogen in utero increase breast and testis cancer risks in
adult life (Ekbom et al, 1992; Michels et al, 1996; Møller and
Skakkebæk, 1997; Swerdlow et al, 1997a). Hormone drug therapy
during pregnancy exposes the mother (at a time of great changes in
her body) and the fetus (in a state of organogenesis and rapid
growth) to an external source of oestrogens.
Exposure to a synthetic oestrogen, diethylstilbestrol (DES), during
pregnancy has been shown to cause anatomical changes in the
genitals of both male and female fetuses (Bibbo et al, 1977; Beral and
Colwell, 1981; Senekjian et al, 1988) and the exposure is associated
with breast cancer of the mother and with benign tumours and cancer
of the reproductive tract of daughters (Beral and Colwell, 1980;
Colton et al, 1993). For other oestrogen and progestin drugs, some
studies show a positive relation to genital malformations, others not
(Heinonen et al, 1977; Goldstein et al, 1989; Briggs et al, 1994). In a
follow-up study, sons exposed prenatally in utero to medroxyproges-
terone had undescended testicles and inguinal hernia more frequently
than control sons, but the difference was not statistically significant
(Jaffe et al, 1990). Prenatal exposure to oestrogen has been reported
to be a risk factor for testicular cancer, cryptorchidism and hypofunc-
tional testes (Depue et al, 1983), and germ-cell tumours of testes and
ovaries (Preston-Martin, 1989); there are no previous studies on
other cancers of the daughter or any cancer of the mother.
It is useful to study malformations and cancers at the same
time: teratogenic and carcinogenic properties of substances often
correlate (Vainio, 1989). For undescended testes and other inborn
anatomical changes in the genitals and testicular cancer a common
aetiology during embryonic development has been suggested
(Møller and Skakkebæk, 1997; Swerdlow et al, 1997b ; Prener
et al, 1996).
The purpose of this study was to investigate whether the use of
female sex hormone drugs during pregnancy is a risk factor for (1)
subsequent breast and other oestrogen-dependent cancers among
mothers and (2) genital malformations in fetuses. As a by-product
of a study investigating the impact of oestrogen and progestin
exposure on the fertility of offspring we had follow-up data on the
children, and took the opportunity to look at the impact on their
risk of cancer, even though the study power for that was very low.
MATERIALS AND METHODS
This study is based on a retrospective cohort. The information on
exposure, confounding factors and immediate outcomes was
collected from patient records in maternity centres in Helsinki and
that on long-term outcomes was collected from national popula-
tion and mortality data and from cancer registers through record
linkage.
Cohorts
Since 1944, free prenatal care has been organized by local munici-
palities. By 1960, 85% of Helsinki women who gave birth had
registered in maternity centres. In the 1950s and 1960s, care was
given mainly by midwives supported by gynaecologists. A stan-
dard maternity care in duplicate was used and one copy was given
to the mother. Visits to health care facilities because of pregnancy
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and all drugs prescribed were to be noted on this card, including
those prescribed by physicians outside the maternity centre.
A complete list of oestrogen and progestin drugs that were on
the Finnish market in the 1950s and early 1960s was made with the
help of old drug catalogues. A systematic sample of half (233 of
470) of the boxes containing the maternity cards (in the Helsinki
municipality archives) was searched to identify all mothers who
had given birth between 1954 and 1963 and who were prescribed
these drugs. For each exposed mother the next mother in the file
who had given birth during the same year and who was not
prescribed hormones was chosen for a control. If the maternity
card indicated that the mother had been sent to a hospital for preg-
nancy-related reasons (18% of the mothers), her records were
studied in the hospital archives. If hormone therapy was noted in
the hospital record of a control, this control became an exposed
mother (1.4% of exposed mothers).
Malformations
Data on malformations were also extracted from the maternity
cards; notes had usually been made by midwives based on the
discharge summary sent from the delivery hospital. Data were
abstracted and classified by a trained research midwife.
Malformations and other problems of the genitals were separately
coded, and other malformations were classified into major (such as
cleft palate, lacking a limb, or hydrocephalus), and minor (e.g. hip
dislocation) and severity unknown.
Cancers of mothers and children
Follow-up was done with the help of life-long personal identifica-
tion (ID) numbers given to all Finns between 1964 and 1967.
Because our cohort was formed of people born before 1964, ID
numbers for the mothers were sought from the Central Population
Register, supplemental by data from local church records and
death certificates. An ID number was found for 99% of the
mothers; the rest had died, emigrated before the ID number was
given or lacked an ID number for a reason that remained unclear.
For 89% of the index births, a child (children) with an ID number
was found. The rest included miscarriages and abortions (7.2%),
early deaths (2.9%) and births of unclear outcome (1.5%).
Dates of emigration and death (after the 1964–1967 period)
were obtained from the Population Register. Deaths before the
1964–1967 period and causes of death were obtained from the
Cause-of-Death Register. Cancers were identified from the
National Cancer Register. It has been in operation since 1953 and
is based on compulsory notifications by physicians, on data from
hospital and laboratory records and on death certificates. The
notification rate and accuracy are high (Teppo et al, 1994). The
registry used a classification system based on the ICD7
(International Classification of Diseases) for the period
1960–1968 and cancers that occurred before or after this period
have been reclassified using the same system of coding.
Analysis
To study early deaths (stillborn and live born not found in death or
population registers) and malformations of the children, all live
and stillbirths (n = 4071) were included. In studying later deaths
and cancer among the offspring, all children with an ID number
(n = 3939) were included. For the study of maternal cancer; all
mothers with an ID number were included (n = 4090).
The original pairs of exposed and control mothers were used to
form the following groups and their control groups: mothers and
children exposed to (1) oestrogen drugs (with or without progestin
drugs) (at least) early in pregnancy, (2) oestrogen drugs (with or
without progestin drugs) only late or at an unknown time, (3) just
progestin drugs (at least) early in pregnancy, (4) just progestin
drugs only late in pregnancy or at an unknown time. Those exposed
to hormone drugs the content of which could not be identified,
together with their controls, were included in the total figures. Early
exposure was defined to include a prescription or an injection in the
first 16 gestation weeks calculated from the last menstrual period,
or if that date was lacking, when the indication for the drug was
either (recurrent) miscarriage or nausea. Individual mothers could
have received more than one drug and, in defining the exposure
group, drugs from various sources (maternity centre, hospital) at
different times were combined. Due to the sampling method, one
mother could appear more than once (6.4% of all mothers), and her
group could be different for different index births. In the analysis of
maternal cancer, each mother was counted only once, and her expo-
sure group was chosen in the order of the groups given above.
Table 1 Mothers’ background characteristicsa
Oestrogenb Progestin only Totalc
Exp Cont Exp Cont Exp Cont
(n) (417) (412) (1566) (1545) (2052) (2038)
Age at first livebirth
Mean (s.d.) 26.3 (5.2) 25.8 (4.9) 25.3 (4.8) 25.0 (4.4) 25.5 (4.9) 25.2 (4.5)*
³ 30, % 20.4 18.0 14.5 11.7* 15.8 12.9**
White collar-workerd, % 36.5 37.4 42.9 39.4 41.6 39.0
Miscarriages prior to index birth, % 38.9 16.3*** 34.5 16.4*** 35.3 16.5***
Index birth
Pre-pregnancy weight, kg, mean (s.d.) 57.3 (7.8) 58.4 (7.6)* 57.5 (7.9) 58.2 (8.2)* 57.5 (7.9) 58.2 (8.1)**
First prenatal visit, wk, mean (s.d.) 12.3 (4.9) 17.2 (7.3)*** 13.2 (5.1) 16.8 (6.9)*** 13.1 (5.2) 17.0 (7.0)***
Other than livebirth, % 6.9 3.0** 5.3 2.7*** 5.5 2.8***
Birthweighte, g, mean (s.d.) 3322 (717) 3477 (572) 3341 (724) 3452 (591)*** 3338 (718) 3455 (589)***
Not breastfeeding, post-partum visit, % 21.6 23.5 25.2 26.7 24.5 25.7
aExp = exposed, cont = control group; statistical testing is between exposed and control groups; *P < 0.05, **P < 0.01, ***P < 0.001. Numbers after means in
parenthesis give standard deviations. bMay include also progestin. cIncludes children with unknown type of exposure. dIn 1971. eIf twins, data for the firstborn.1094 E Hemminki et al
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For the estimations of incidence, the number of cancers was
divided by person-years calculated from the date of the index birth
(in the case of mothers who appeared more than once, from the
index birth defining her exposure group) to March 1997, emigra-
tion or death, whichever was first. Cancers occurring prior to the
index birth were ignored. c2-tests and t-tests were used to assess
the statistical significance of the differences. Odds ratios (ORs)
and their 95% confidence intervals (CIs) were calculated for
cancer incidence. Differences between the groups were adjusted
by logistic regression for the continuous variables: ‘age at first
live birth’, ‘number of live births’, ‘pre-pregnancy weight’ as
confounders. In a second analysis, ‘miscarriages prior to the index
birth’ (continuous) was added, and in a third, ‘current pregnancy
ending in miscarriage’ (yes-no) was further added.
RESULTS
Of the 100 different drug trade-names containing oestrogen and
progestins that were on the market, 32 had been used. The most
common drug was Primolut® (37% of the drugs mentioned). It
contained either progesterone, oxyprogesterone, ethisterone, or
norethisterone (depending on the drug form). The next most
common ones were Progesteron® (either progesteron or ethis-
terone) (26%), Gestanon® (allylesterone) (12%) and Di-Pro® (a
combination of estradiol or ethinylestradiol and progesterone or
ethisterone) (9%). There was no case of DES-exposure. The most
common indications for hormone drugs were threatened mis-
carriage (47%, counted from the first drug exposure), recurrent
miscarriage (9%), and threatened premature birth (7%). The length
of the therapy could be calculated for only half of the women, and
for 68% of these the exposure had been for less than 4 weeks.
However, most (77% of all drugs mentioned) were administered
by injection and in the case of debot (slow-releasing) forms the
influence could have lasted for weeks.
In most respects the exposed and control mothers were similar
(Table 1). Some differences were statistically significant but, in
absolute terms, the differences were small. However, previous to
the index birth, the exposed mothers had more often had pregnan-
cies not ending in a live birth. Their index pregnancies, by defini-
tion, were more problematic than those of the control mothers, and
the children were more often of low birth-weight.
Mothers
During the follow-up period (on average 35 years) the number of
exposed and control mothers who developed cancer was equal
(Table 2). When mothers who had only basal cell carcinoma of the
skin, in situ cervical cancer and other ‘benign’ cancers were
excluded, the similarity between the groups remained.
Numbers were largest for cancer of the breast, and for this site
the ORs were particularly evenly distributed between the exposed
and control women (Table 2). When examined by a more detailed
grouping, there was an indication that mothers exposed to
oestrogen in early pregnancy developed breast cancer more
frequently (OR = 1.30, CI 0.57–2.97) and mothers exposed to
oestrogen in late pregnancy less frequently (OR = 0.49, CI
0.15–1.62), but the numbers were small and the confidence inter-
vals large. Timing of progestin exposure did not have any influ-
ence on risk. Adjustment for confounding factors did not change
the results (Table 2).
Ovarian and cervical cancer were more common among
oestrogen-exposed mothers and less common among progestin-
Table 2 Follow-up on mothers until 1997a, cancers after the index birth (in 1954–1963)
Oestrogenb Progestin only Totalc
Exp Cont Exp Cont Exp Cont
(Number of mothers) (417) (412) (1566) (1545) (2052) (2038)
All cancerse
Incidence (n) 34.7 (49) 39.6 (56) 41.7 (221) 41.4 (212) 40.9 (284) 40.9 (278)
OR (CI) 0.87 (0.59–1.28) 1.01 (0.84–1.22) 1.00 (0.85–1.18)
Adj. OR (CI) 0.85 (0.56–1.28) 1.02 (0.83–1.25) 1.00 (0.83–1.20)
Breast cancer
Incidence (n) 12.0 (17) 12.7 (18) 13.4 (71) 14.5 (74) 13.7 (95) 14.0 (95)
OR (CI) 0.95 (0.49–1.83) 0.93 (0.67–1.29) 0.98 (0.74–1.30)
Adj. OR (CI) 0.96 (0.49–1.90) 0.94 (0.69–1.32) 1.00 (0.74–1.34)
Ovarian cancer
Incidence (n) 2.1 (3) 0.7 (1) 1.3 (7) 2.3 (12) 1.4 (10) 2.2 (15)
OR (CI) 3.00 (0.31–28.9) 0.56 (0.22–1.43) 0.65 (0.29–1.45)
Adj. OR (CI) 3.28 (0.34–32.0) 0.69 (0.27–1.79) 0.73 (0.32–1.63)
Cervical cancerd
Incidence (n) 5.0 (7) 3.5 (5) 2.6 (14) 3.9 (20) 3.0 (21) 3.7 (25)
OR (CI) 1.40 (0.44–4.41) 0.68 (0.34–1.34) 0.82 (0.46–1.47)
Adj. OR (CI) 1.51 (0.47–4.83) 0.61 (0.30–1.24) 0.83 (0.46–1.50)
Uterine cancer
Incidence (n) 1.4 (2) 0 (0) 2.6 (14) 1.4 (7) 2.3 (16) 1.0 (7)
OR (CI) – 1.94 (0.78–4.79) 2.24 (0.92–5.44)
Adj. OR (CI) – 1.67 (0.66–4.23) 1.98 (0.80–4.87)
aExp = exposed, cont = control group, OR = odds ratio, CI = 95% confidence limits, Adj. = adjusted for age at first livebirth, number of live births, pre-pregnancy
weight. Incidence is per 10 000 person-years; follow-up until 1997, emigration or death (mean 35 years). In logistic regression ‘cont’ is the reference group.
bMay include also progestin. cIncludes children with unknown type of exposure. dWith cancer in situ. eEach mother only once.Female hormone drugs during pregnancy 1095
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exposed mothers (Table 2), but the differences were not statisti-
cally significant. When the cases of cancer in situ were excluded,
the relative differences remained the same.
Uterine cancer was more common among the exposed mothers,
even when examined in more detail by timing of exposure. The
difference was not statistically significant, but was more sugges-
tive of a genuine elevation of risk than any of the results for the
other genital cancers.
Further adjustment for previous miscarriages or miscarriages in
the index births did not notably change the adjusted odds ratios for
cancers shown in Table 2.
Colon cancer was more common among the exposed mothers,
but not statistically significantly so (OR = 1.59, CI = 0.66–3.85).
There was more lung cancer among mothers who had received
progestin drugs in early pregnancy (OR = 10.5, CI = 1.36–81.4).
According to the Cause-of-Death Register there were 65 cancer
deaths among the exposed mothers and 77 among the controls.
The difference was due to more breast cancer deaths among the
control (n = 20) than exposed mothers (n = 11, P = 0.053). Other
reproductive cancer deaths were rarer and relatively evenly
distributed between the exposed and control mothers.
Children
The total number of malformations, as well as the number of male
genital problems recorded on the maternity cards, was higher
among the exposed children (Table 3). The genital problems were:
hydrocele (two boys), hypospadia (two), operation on the scrotum
(one for haematoma, one for necrotic testis). With the exception of
one child, mothers of these boys had been given oestrogen- and/or
progestin-containing intramuscular injections in early pregnancy;
the number of recorded injections varying from 2 to 11. The mother
of one child had had progestin injections 3 months before delivery.
There were more early deaths in the exposed groups, and fewer
in later life. However, the differences were not significant. In the
follow-up period (mean 36 years), incidence of cancer and the
ORs were somewhat higher among exposed men than control men,
but the opposite was found for women. Again, however, the
numbers were small and all differences were statistically non-
significant. Among men, no cancers of the male genitalia
occurred. Among women, there were seven cases of breast cancer
(three exposed, four controls), one of ovarian cancer (control), and
three of cancer of the uterine cervix (one exposed, two controls).
There were no cases of clear cell adenocarcinoma or cancer in situ
of the cervix uteri. Cancer as the main cause of death was recorded
for four exposed and one control child.
DISCUSSION
Our study did not support the hypothesis that oestrogen or prog-
estin drug therapy during pregnancy causes cancer in the mother
Table 3 Numbers of malformed children by exposure groupa
Oestrogenb Progestin only Totalc
Exp Cont Exp Cont Exp Cont
(Denominator) (409) (425) (1484) (1601) (1963) (2108)
Male genital 3 0 3 0 6 0**
‘Related’d 02 34 3 6
Other major 4 0* 15 8 19 9*
Other minor 2 2 31 17* 35 21*
Other, severity unknown 5 2 8 2* 13 4*
Total 14 6 60 31*** 76 40***
aStatistical testing is between exposed and control groups, *P < 0.05, **P < 0.01, ***P < 0.001. bMay contain also progestin. cIncludes children with unknown
type of exposure. dThe group ‘related’ includes children with swollen breasts (2 exposed and 2 controls), microanus (1 exposed), bleeding from the vagina and
phimosis (both controls), and one unclear diagnosis, apparently a perianal fistula (1 control).
Table 4 Follow-up of children until the age of 34–43-yearsa
Oestrogenb Progestin only Totalc
Exp Cont Exp Cont Exp Cont
Children followed, n (389) (414) (1432) (1557) (1890) (2049)
Cancer cases
Men 2 1 7 5 9 7
Women 2 4 8 12 10 16
Cancer incidenced
Men 2.8 1.5 2.8 1.8 2.7 2.0
Women 3.0 5.3 3.3 4.7 3.1 4.6
Odds ratios (95% CI)e
Men 1.95 (0.17–21.5) 1.58 (0.50–4.97) 1.40 (0.52–3.76)
Women 0.57 (0.11–3.13) 0.69 (0.28–1.70) 0.67 (0.30–1.47)
aStatistical testing is between exposed and control groups, *P < 0.05, **P < 0.01, ***P < 0.001. bMay contain also progestin. cIncludes children with unknown
type of exposure. dPer 10 000 person-years; follow-up until 1997, emigration or death (mean 36 years). eControl = 1, CI = confidence interval.1096 E Hemminki et al
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or in offspring later in life. However, it could be that confounding
by unmeasured factors and weak exposure contribute to the
observed results. The exposed mothers, by definition, had had
more problems during the index pregnancy, but these also occurred
in prior pregnancies (as judged by the number of miscarriages).
Most hormones were prescribed for indications such as miscar-
riage or preterm birth or the threat of them, and the birthweights of
the children of the index births were lower. If these indicate lower
endogenous oestrogen production during pregnancy (Ekbom et al,
1992; Michels et al, 1996), then low endogenous oestrogen
production may be a negative confounder in our study masking
any impact the hormone drugs may have had. Furthermore, nega-
tive confounding could have been caused by other differing char-
acteristics not recorded in our data sources. The finding that there
were more lung cancers among progestin-exposed mothers may
indicate that more of these mothers smoked or that they smoked
more. Smoking could have caused the pregnancy problem (Walsh,
1994) and decreased the incidence of hormone-dependent cancers,
such as uterine cancer (Wald and Hackshaw, 1996).
Details of the timing and length of therapy were not always
given, but some of the therapies were short. If there is a threshold,
with dosages only effective above a certain minimum, or if there is
a very narrow time-window during gestation when a patient is
vulnerable, then many of the women were not truly exposed.
Furthermore, a great variety of different types of oestrogen and
progestins were prescribed, and even minor modifications in the
molecular structure of a drug formulation can substantially effect
the biological properties.
For the study of cancer among the offspring of the exposed
women the numbers were very small but, nonetheless, gave no
indication of a large increase in risk. After 10 or 20 years, when the
subjects are in an age-group that is more affected by cancer, it will
be worth studying the children anew. There were more malforma-
tions among exposed children. This suggests that oestrogen and
progestin exposure could be a risk-factor for subsequent cancers
that would be detected only by longer follow-up or in a larger
study. On the other hand, causality may have been the other way
around: a malformation in the fetus may have caused symptoms
resulting in the hormone therapy.
It is notoriously difficult to study drug effects occurring 40 years
after their use in a scenario of rapidly changing clinical practice
and with a large number of pharmacological modifications.
Confounding by indications for treatment is an intrinsic problem
that can only be properly resolved in a clinical trial. To our knowl-
edge no such trial with progestins or oestrogen other than DES
have been carried out, and these trials are unlikely to be under-
taken in view of current understanding of the ineffectiveness of the
therapy (Goldstein et al, 1989).
The importance of long-term follow-up studies on hormone
drug therapy during pregnancy can be argued on two grounds.
First, even though treating pregnancy problems with oestrogen
drugs is no longer popular, the treatment of threatened miscarriage
with progestin and some other hormones still occurs. Furthermore,
women are exposed intentionally and unintentionally to hormone
drugs, either during pregnancy or immediately before it. In the
latter event, if the half-life of the drug is long it may still be in the
body during pregnancy. Such exposures may result from failed
long-term intradermal or injection contraceptives, postcoital
contraceptive pills, treatment of (assumed) premenstrual
syndrome, assisted conception techniques (IVF and others) and
oestrogen-containing natural products. Secondly, studying effects
on cancer may be educational in illustrating how important it is to
make a full evaluation of the outcomes of a drug therapy during
pregnancy, including long-term effects. Such illustration may
contribute to better criteria for defining the safety of drugs.
Acknowledging the possibility of long-term effects is also an argu-
ment for taking a conservative approach in treating pregnant
women with drugs, and also for use of a small number of drugs
instead of many different modifications, to facilitate more
complete evaluation.
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